The long range goal of this program is to improve the therapy of human cancer with arabinonucleoside analogs. This project is concerned with the mechanism responsible for the selectivity of established and new arabinonucleosides related to cytosine, adenine and guanine in murine leukemia and human lumphoid model systems. The following specific aims will be sought: Further aspects of the cytotoxic mechanism of newly synthesized purine and pyrimidine deaminase-resistant 2'-0-nitronucleosides termed nitrara-A and nitrara-C of arabinosyl-adenine and -cytosine, respectively in human lymphoblastoid lines; use radiolabeled nitrara-C and high pressure liquid chromatography to determine its metabolic fate in plasma and activation (phosphorylation and incorporation into nucleic acids) in murine leukemia and in human lymphoblastoid lines, including those of T and B origin, with demonstrated differential sensitivity to the drug; Evaluate in collaborative studies with colleagues from this institution and elsewhere the antitumor and antiviral effects of the new nitrate nucleosides and purine nucleoside phosphorylase-resistant 9-Beta-D-arabinosylguanine in animal model systems; purify and characterize the nucleotidase enzymes in human lymphoid tissues for degradation of active arabinonucleotides and deoxynucleotides; specific antibodies to nucleotidases will be obtained to aid in the identification of the enzyme(s) responsible in human lymphoblastoid of T and B origin (wild type and mutants) for the catabolism of the arabinonucleotide analogs. Nucleotidase activity and analog nucleotide retention will be examined in sensitive and resistant cell lines to further define the relationship of these two to arabinonucleoside metabolism and selectivity.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Sarup, J C; Johnson, M A; Verhoef, V et al. (1989) Regulation of purine deoxynucleoside phosphorylation by deoxycytidine kinase from human leukemic blast cells. Biochem Pharmacol 38:2601-7
Johnson, M A; Ahluwalia, G; Connelly, M C et al. (1988) Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem 263:15354-7
Fridland, A; Verhoef, V (1987) Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. Semin Oncol 14:262-8
Sarup, J C; Fridland, A (1987) Identification of purine deoxyribonucleoside kinases from human leukemia cells: substrate activation by purine and pyrimidine deoxyribonucleosides. Biochemistry 26:590-7
Johnson, M A; Johns, D G; Fridland, A (1987) 2',3'-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy. Biochem Biophys Res Commun 148:1252-8
Verhoef, V; Ashmun, R; Fridland, A (1986) Rhodamine 123 and flow cytometry to monitor the cytotoxic actions of nucleoside analogues in nondividing human lymphocytes. Anticancer Res 6:1117-21
Fridland, A; Connelly, M C; Robbins, T J (1986) Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase. Cancer Res 46:532-7
Verhoef, V; Fridland, A (1985) Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 45:3646-50
Fridland, A; Verhoef, V (1985) Metabolism and selectivity of arabinonucleoside in human lymphoid cells. Proc Soc Exp Biol Med 179:456-62